BMRN BioMarin Pharmaceutical Inc.

83.30
-1.32  -1.56%
Previous Close 84.62
Open 84.62
Price To book 5.49
Market Cap 14.33B
Shares 171,987,000
Volume 750,495
Short Ratio 6.76
Av. Daily Volume 1,296,300

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536861
  2. 8-K - Current report 162059117
  3. 8-K - Current report 162044215
  4. 8-K - Current report 162031341
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161970333

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 interim data released July 2016. Update due in December 2016. Phase 2b to be initiated 2H 2017.
BMN 270
Hemophilia A
Approved Feb 14 2014
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
Phase 2 updated data released October 2016. Phase 3 trial to be initiated end of 2016.
Vosoritide
Achondroplasia
Phase 3 data released March 2016. Primary endpoint hit. Key secondary endpoint missed. NDA (BLA) filing to be filed 1Q 2017.
PEG-PAL
Phenylketonuria (PKU)
Program terminated June 2016
Reveglucosidase alfa (BMN 701)
Pompe Disease
CRL issued January 14 2016
Kyndrisa
Duchenne Muscular Dystrophy (DMD)
PDUFA date extended by three months to April 27 2017
Cerliponase alfa
Batten Disease

Latest News

  1. We’re in the year of the biotech buyout, and here are five prime targets
  2. Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential
  3. BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : January 18, 2017
  4. Top Stocks to Buy Now That the 21st Century Cures Act Has Passed
  5. BioMarin CEO: Positive results for hemophilia treatment
  6. BioMarin Pharma cites positive results for hemophilia treatment
  7. BioMarin to Provide Update to Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A at 35th Annual J.P. Morgan Healthcare Conference
  8. Could Sanofi Acquire BioMarin In Wake Of Amgen LDL Brouhaha?
  9. Biotech Investing: 3 Bold Predictions for 2017
  10. Blog Coverage Affimed Join Hands with MD Anderson Cancer Center for Clinical Immuno-Oncology Development Collaboration
  11. The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
  12. BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : January 4, 2017
  13. 3 Overlooked Drug Stocks to Watch Out for in 2017
  14. BioMarin to Present at 35th Annual J.P. Morgan Healthcare Conference in San Francisco
  15. BioMarin (BMRN) Raised to Buy: Should You Add the Stock?
  16. 3 Precision Medicine Stocks to Buy in January
  17. Time for biotech to boom ... or bust?
  18. RBC Likes Large Cap Biotech Leaders for 2017
  19. BioMarin Pharmaceutical, Inc. – Value Analysis (NASDAQ:BMRN) : December 21, 2016
  20. BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : December 20, 2016

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536861
  2. 8-K - Current report 162059117
  3. 8-K - Current report 162044215
  4. 8-K - Current report 162031341
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161970333
  6. 8-K - Current report 161955695
  7. 8-K - Current report 161825314
  8. 424B5 - Prospectus [Rule 424(b)(5)] 161822276
  9. 424B5 - Prospectus [Rule 424(b)(5)] 161815355
  10. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 161814308